HLB, awaiting new drug approval in the U.S. for its liver cancer drug Rivoceranib, said Tuesday its liver cancer treatment improved the conditions of patients who were deemed inoperable.
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib as first-line treatment in unresectable HCC, based on data from the randomized, open-label, international phase 3 CARES-310 trial.